Although bronchial hyperresponsiveness to cholinergic agents is a main feature of asthma, the role of anticholinergic drugs in chronic asthma management has been largely underestimated.

Omalizumab biosimilar is under clinical development by Mabpharm and currently in Phase III for Chronic Urticaria Or Hives.

There are three major problems with asthma care in the USA and misuse of asthma drug therapy contributes to each. Asthma patients suffer from symptoms regularly partly because healthcare providers ...

While the exact cause of asthma is unknown, certain genetic factors can increase the risk of developing the disease.

The tool, developed by researchers at Pitt, could allow doctors to diagnose subtypes of the disease without putting patients ...

PF-07832837 is under clinical development by Pfizer and currently in Phase I for Asthma. According to GlobalData, Phase I drugs for Asthma have a 74% phase transition success rate (PTSR) indication ...

A NEW nasal swab has been found to diagnose asthma in children far quicker than previous methods. The test, developed by American researchers, is able to diagnose specific subtypes of asthma.

"This study really looked at preventing accidental ingestions, preventing anaphylaxis, and just making life a little easier ...

Emerging research suggests that certain diabetes medications could offer benefits beyond blood sugar control, potentially ...

A noninvasive approach could help clinicians prescribe medications more precisely for patients according to endotype.